🌟Unprecedented fragment-based screening using Spectral Shift for GPCRs Fragment-based drug design presents a unique opportunity to identify novel binding sites for membrane proteins. 🌐 Join us and Eurofins Discovery on 17 October at 16:00 BST to learn how our experts: Vanessa Porkolab, PhD, Alexis Moreno, PhD, and Maud Sigoillot, PhD, and internal capabilities can speed up your drug discovery processes taking advantage of their expertise in GPCRs protein production and screening with the most recent biophysics technologies. Don't miss this opportunity to gain valuable insights into the future of fragment-based screening. 🔹 Register now: https://bit.ly/4cEK6Uh #drugdiscovery #screening #biophysics #membrane #proteins #spectralshift
This content isn’t available here
Access this content and more in the LinkedIn app